We are live on
!
Find out more
VC
Vivo Capital Portfolio holdings
AUM
$1.2B
1-Year Est. Return
911.44%
This Fund
S&P 500
This Quarter
Est. Return
+45.18%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.21B
AUM Growth
+$126M
(+12%)
Cap. Flow
-$107M
Cap. Flow
% of AUM
-8.85%
Top 10 Holdings %
Top 10 Hldgs %
77.54%
Holding
46
New
4
Increased
3
Reduced
10
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZBIO
Zenas BioPharma
ZBIO
|
+$21.3M |
| 2 |
TERN
Terns Pharmaceuticals
TERN
|
+$5.86M |
| 3 |
Corvus Pharmaceuticals
CRVS
|
+$5.38M |
| 4 |
Trevi Therapeutics
TRVI
|
+$4.79M |
| 5 |
Tenax Therapeutics
TENX
|
+$755K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLNO
Soleno Therapeutics
SLNO
|
+$49.1M |
| 2 |
Dyne Therapeutics
DYN
|
+$20.7M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$19.6M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
+$15.4M |
| 5 |
Cogent Biosciences
COGT
|
+$10.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RGLS
26
DELISTED
Regulus Therapeutics
RGLS
| $7.85M | 0.65% |
5,000,000
| – | – |
|
27
ALX Oncology
ALXO
$260M
| $7.34M | 0.61% |
4,034,522
-185,526
| -4% | -$690K |
|
28
Compass Therapeutics
CMPX
$357M
| $6.54M | 0.54% |
3,556,023
| – | – |
|
|
IOBT
29
DELISTED
IO Biotech
IOBT
| $6.48M | 0.54% |
6,173,439
| – | – |
|
|
ADVM
30
DELISTED
Adverum Biotechnologies
ADVM
| $5.85M | 0.48% |
833,333
| – | – |
|
|
31
Trevi Therapeutics
TRVI
$2.54B
| $5.39M | 0.45% |
+1,612,903
| New | +$4.79M |
|
32
Verastem
VSTM
$500M
| $4.6M | 0.38% |
1,538,461
| – | – |
|
33
enGene Therapeutics
ENGN
$119M
| $4.48M | 0.37% |
678,705
| – | – |
|
34
Corbus Pharmaceuticals
CRBP
$165M
| $3.44M | 0.28% |
166,794
| – | – |
|
35
Bolt Biotherapeutics
BOLT
$7.65M
| $2.28M | 0.19% |
176,065
| – | – |
|
|
ALLK
36
DELISTED
Allakos
ALLK
| $1.93M | 0.16% |
2,956,110
-31,890
| -1% | -$23.1K |
|
37
Unicycive Therapeutics
UNCY
$138M
| $1.82M | 0.15% |
447,015
+100,000
| +29% | +$402K |
|
38
Aligos Therapeutics
ALGS
$28.5M
| $1.23M | 0.1% |
141,879
-2
| -0% | -$25 |
|
39
Codexis
CDXS
$156M
| $1.2M | 0.1% |
388,144
| – | – |
|
|
DBVT
40
DBV Technologies
DBVT
$804M
| $948K | 0.08% |
270,887
| – | – |
|
41
Q32 Bio
QTTB
$451M
| $917K | 0.08% |
20,559
| – | – |
|
|
42
Tenax Therapeutics
TENX
$517M
| $721K | 0.06% |
+208,333
| New | +$755K |
|
43
Precision BioSciences
DTIL
$182M
| $41.9K | ﹤0.01% |
4,675
| – | – |
|
|
44
Tarsus Pharmaceuticals
TARS
$2.68B
| – | – |
-565,550
| Closed | -$15.4M |
|
45
Zai Lab
ZLAB
$2.05B
| – | – |
-531,198
| Closed | -$9.21M |
|
|
WHWK
46
Whitehawk Therapeutics
WHWK
$196M
| – | – |
-509,572
| Closed | -$744K |
|
Similar funds
SGDR
FCCPG
AIM
SC
MB
CCM
LWIC
TIM
Vivo Capital's Q3 2024 Portfolio in Review
As of Q3 2024, Vivo Capital held 46 positions worth $1.21B, up 12% from $1.08B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Vivo Capital withdrew a net $107M in Q3 2024, closing 3 positions and reducing 10 holdings. Its most notable exit was Tarsus Pharmaceuticals, an estimated $15.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Vivo Capital opened a new position in Zenas BioPharma worth $20M.
- Vivo Capital's largest Q3 2024 buy was Zenas BioPharma: 1,183,260 shares worth $20M.
- Vivo Capital added most to Terns Pharmaceuticals in Q3 2024, an estimated $5.86M increase.
- Vivo Capital's biggest Q3 2024 reduction was Soleno Therapeutics, cutting an estimated $49.1M.
- Vivo Capital fully exited Tarsus Pharmaceuticals in Q3 2024, selling an estimated $15.4M.
- Vivo Capital's ten largest holdings make up 78% of its $1.21B portfolio in Q3 2024.
- Vivo Capital opened 4 new positions and closed 3 in Q3 2024.
- Vivo Capital's portfolio value rose 12% quarter-over-quarter to $1.21B.
Based on Vivo Capital's 13F filing for Q3 2024, filed 13 Nov 2024.